Although the Prospective Randomized Evaluation of the LAA Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy (PREVAIL) trial (mimicking the original PROTECT AF protocol) failed to demonstrate non-inferiority of LAAO compared with warfarin, a significantly lower adverse event rate was recorded for LAAO.
Both accompanied their respective randomized clinical trials, PROTECT-AF (Watchman Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation) and PREVAIL (Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device In Patients with Atrial Fibrillation versus Long Term Warfarin Therapy), which used the same endpoints (primary efficacy of composite of stroke, systemic embolism, cardiovascular/unexplained death, and safety).
Such a well-conducted controlled study can even prove that the use of parachutes does not statistically reduce death or major traumatic injury when jumping from an aircraft in the first randomized evaluation of this intervention.
In a prospective, multi-center, cluster-randomized evaluation study we will develop, implement and evaluate a training program for oncology physicians advising their patients on complementary and integrative medicine.
We estimate QoL and annual hospital costs associated with a range of adverse events of interests using the individual participant data from the Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification (REVEAL) trial.
我們使用來自通過脂質修飾（REVEAL）試驗對 Anacetrapib 的影響進行隨機評估的個體參與者數據來估計與一系列感興趣的不良事件相關的 QoL 和年度醫院成本。
Methods Data were available from 14 767 patients with AF from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial and 8651 patients with AF from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial in this cohort study.
方法 數據來自阿哌沙班用於減少心房顫動中卒中和其他血栓栓塞事件 (ARISTOTLE) 試驗的 14767 名 AF 患者和長期抗凝治療隨機評估 (RE-LY) 試驗的 8651 名 AF 患者的數據。這項隊列研究。
SETTING: Twenty-two PICUs participating in the multisite clinical trial, Randomized Evaluation of Sedation Titration for Respiratory Failure (U01 HL086622) and the ancillary study (Biomarkers in Children with Acute Lung Injury).
In a controlled, open-label trial of hospitalized COVID-19 patients, the Randomized Evaluation of COVID-19 Therapy (RECOVERY) Collaborative Group found that the use of dexamethasone, a cheap generic drug commonly used to treat a variety of inflammatory conditions, resulted in lower 28-day mortality in COVID-19 patients receiving respiratory support.
Background The RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial demonstrated that higher-risk patients with atrial fibrillation had lower rates of stroke or systemic embolism and a similar rate of major bleeding, on average, when treated with dabigatran 150mg compared to warfarin.
Siegbahn and colleagues used multiplex protein screening to identify novel biomarkers of OACrelated major bleeding risk in 4200 patients with AF enrolled in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events) trial (identification cohort) and 1368 patients with AF enrolled in the RELY (Randomized Evaluation of LongTerm Anticoagulation Therapy) trial (replication cohort).
Siegbahn 及其同事使用多重蛋白質篩查來確定 4200 名參加 ARISTOTLE（阿哌沙班用於減少中風和其他血栓栓塞事件）試驗（識別隊列）的 AF 患者和 1368 名參加 RELY 的 AF 患者的 OAC 相關大出血風險的新生物標誌物（長期抗凝治療的隨機評估）試驗（複製隊列）。
A clinical interpretation of the Randomized Evaluation of COVID-19 Therapy (RECOVERY) study was performed to provide a useful tool to understand whether, when, and to whom dexamethasone should be administered during hospitalization for COVID-19.
We systematically searched PsycINFO and MEDLINE for randomized evaluations of parenting programs to improve sibling interactions, to estimate their effects on sibling interactions, and identified eight studies (136 effect sizes): four evaluations of behavior management, three evaluations of mediation; and one evaluation of behavior management combined with mediation.
The Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial provided rapid, emphatic evidence that hydroxychloroquine (1) and lopinavirritonavir (2) were ineffective, and then that dexamethasone could reduce the risk of death in the sickest patients (3).
In line with the outcomes from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial and prospective meta-analysis, the World Health Organization (WHO) recommended use of systemic corticosteroid therapy in patients with severe and critical COVID-19.
The study first tested whether a CETP allele score was associated with morbidity and mortality, when scaled to genetically lower levels of non-high-density lipoprotein (HDL) cholesterol (ie, 17 mg/dL), corresponding to the reduction observed for anacetrapib vs placebo in the Randomized Evaluation of the Effects of Anacetrapib Through Lipid-Modification (REVEAL) trial.
Using a randomized evaluation in Namibia’s communal rangelands, we find that a comprehensive four-year program to support community-based rangeland and cattle management led to persistent and large improvements for eight of thirteen indices of social and behavioral outcomes.
This observation is in line with the results of the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48) and the systematic review (2) of four pivotal RCTs for stroke prevention in patients with AF [the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation), ENGAGE AF-TIMI 48 (edoxaban), RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy With Dabigatran Etexilate), and ROCKET AF (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and NonCentral Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation) trials; n=71,683], which reported a lower risk of stroke, including hemorrhagic stroke and systemic embolism, along with all-cause mortality for non-vitamin K antagonist oral anticoagulants (NOACs) as compared with vitamin K antagonists [risk ratio (RR): 0.
這一觀察結果與 ENGAGE AF-TIMI 48 試驗（在心房顫動中使用 Xa 因子進行有效抗凝 - 心肌梗死溶栓研究 48）的結果以及對預防中風的四項關鍵 RCT 的系統評價 (2) AF 患者 [ARISTOTLE（阿哌沙班用於預防房顫患者中風）、ENGAGE AF-TIMI 48（艾多沙班）、RE-LY（達比加群酯長期抗凝治療的隨機評估）和 ROCKET AF（An利伐沙班與華法林預防非瓣膜性心房顫動患者中風和非中樞神經系統系統性栓塞的療效和安全性研究）試驗； n = 71,683]，報告與維生素 K 拮抗劑相比，非維生素 K 拮抗劑口服抗凝劑 (NOAC) 的卒中風險較低，包括出血性卒中和全身性栓塞，以及全因死亡率 [風險比 (RR)： 0。
The largest trial to date is the Randomized Evaluation of COVID19 Therapy (RECOVERY) trial, in which a total of 6425 hospitalized patients with COVID-19 were randomly assigned to receive dexamethasone (n = 2104) or usual care (n = 4321).
Retrospective cohort study using data from the Randomized Evaluation of Normal versus Augmented Level of Renal Replacement Therapy trial that enrolled 1,433 critically ill patients with AKI and treated with CRRT between December 2005 and November 2008 across 35 intensive care units in Australia and New Zealand.
We assessed functional status at baseline, discharge, and six months post-pediatric intensive care unit discharge and HRQL 6 months post-discharge in 2 week to 17 year olds mechanically ventilated for acute respiratory failure in the Randomized Evaluation of Sedation Titration for Respiratory Failure trial.
During a mass media campaign accompanying the launch of the Maximum Diva Woman’s Condom (WC) in Lusaka, Zambia, a cluster-randomized evaluation was implemented to measure the added impact of a peer-led interpersonal communication (IPC) intervention on the awareness and uptake of the new female condom (FC).
在讚比亞盧薩卡推出 Maximum Diva 女性安全套 (WC) 的大眾媒體宣傳活動期間，實施了集群隨機評估，以衡量同伴主導的人際溝通 (IPC) 干預對意識和吸收的額外影響新的女用避孕套 (FC)。
Methods We analyzed subjects enrolled in the Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine trial (ROPA-DOP; NCT01901809) for the presence of RVD and compared clinical outcomes based on treatment assignment to DA.
方法 我們分析了參加急性心力衰竭和多巴胺試驗（ROPA-DOP；NCT01901809）的心力衰竭保留射血分數患者隨機評估受試者是否存在 RVD，並根據 DA 治療分配比較臨床結果。
The results of this study support the findings from a posthoc analysis of the Randomized Evaluation of Long Term Anticoagulation Therapy trial that showed a faster decline in mean eGFR in individuals with atrial fibrillation randomized to warfarin as compared to dabigatran.
The Randomized Evaluation of Sedation Titration for Respiratory Failure trial (RESTORE) trial has revealed that a goal directed sedation protocol does not reduce the duration of invasive ventilation in critically ill children.
In the more recent randomized Evaluation of the Xience Everolimus Eluting Stent vs Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) study, the separate analysis of 30-day MI incidence shows a clear superiority of PCI (3.
In the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran Versus Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial, the primary outcome of major bleeding or clinically relevant nonmajor bleeding was lower with dabigatran dual therapy versus warfarin triple therapy in patients with atrial fibrillation who underwent PCI.
In alignment with the VHA's learning health care system initiative, a multidisciplinary team designed a randomized evaluation of a policy approach to mandating case reviews of very-high-risk patients identified by STORM and the impacts of patient inclusion versus exclusion in mandated STORM case reviews using a stepped-wedge design.
We derived and validated a prediction model for ischemic stroke/systemic embolism and major bleeding in patients with atrial fibrillation from the 3 treatment arms of the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy With Dabigatran Etexilate) (n=11 955 in derivation cohort, n=6158 in validation cohort).
我們從 RE-LY 試驗（達比加群酯長期抗凝治療的隨機評估）（n=11 955）的 3 個治療組中推導出並驗證了房顫患者缺血性卒中/全身性栓塞和大出血的預測模型在推導隊列中，驗證隊列中 n = 6158）。
ABSTRACT In the context of a training program’s randomized evaluation, where estimating wage effects is of interest, we propose employing bounds that control for sample selection as a model-based statistic to conduct randomization-based inference à la Fisher.
摘要在培訓計劃的隨機評估的背景下，其中估計工資效應是有意義的，我們建議採用控製樣本選擇的界限作為基於模型的統計數據來進行基於隨機化的推斷 à la Fisher。
Methods Subjects enrolled in the Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine (ROPA-DOP Trial; NCT 01901809) were analyzed for baseline demographic and clinical variables stratified by AF status.
方法 對參加急性心力衰竭和多巴胺保留射血分數患者心力衰竭隨機評估（ROPA-DOP 試驗；NCT 01901809）的受試者進行基線人口統計學和臨床變量按 AF 狀態分層的分析。
Could a partial subsidy for child education increase child labor? Using data from the randomized evaluation of a conditional cash transfer program (CCT) in the Philippines, we find that children who were neither in school nor work in the absence of the program not only increased school participation but also increased work for pay.
We evaluated lipoprotein subclasses in patients, randomly selected from REASON (Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes) Trial participants, with type-2 diabetes treated with either anagliptin or sitagliptin.
In a multicentre, randomized-controlled, phase III trial in complex cardiovascular surgery (Randomized Evaluation of Fibrinogen vs Placebo in Complex Cardiovascular Surgery: REPLACE), single-dose human fibrinogen concentrate (FCH) was associated with the transfusion of increased allogeneic blood products (ABPs) versus placebo.